급성 및 만성 간질환에서 C형 간염바이러스 항체(anti-HCV)양성률

김삼용,성자원,김병호,이기천,허승식,길준영,정현용,이헌영,김영건 충남대학교 의과대학 지역사회의학연구소 1992 충남의대잡지 Vol.19 No.2

The prevalence of antibody against hepatitis C virus (anti-HCV) was investigated in 331 patients with various liver diseases from April 1992 to September 1992. The presence of anti-HCV was detected by Lucky HCD EIA test in 331 cases and by (Ortho HCV Antibody ELISA test 148 patients) The results are summarized as follows: 1. Overall, antibody to HCV(anti-HCV) was positive in 37(11%) of 331 patients with various liver diseases. 2. 16(11%) of 144 patients with chronic hepatitis, 2(5%) of 37 patients with alcoholic liver disease, 17(22%) of 76 patients with liver cirrhosis and 2(5%) of 38 HBsAg carriers were positive for anti-HCV.None of 12 patients with acute hepatitis, 11 patients with drug induced hepatitis and 13 patients with hepatocellular carcinoma was anti-HCV positive. 3. HBsAg positivity in patients who had anti-HCV was 24%(9/37). 4. A positive correlation was found between Lucky HCD and Ortho HCV test. Of 128 Lucky HCD negative cases, 124 cases were negative for Ortho HCV ELISA and 4 cases were positive for Ortho HCV ELISA Of 20 Lucky HCD positive cases, 11 cases were positive for Ortho HCV ELISA and 9 cases were negative for Ortho HCV ELISA. These results suggest that hepatitis C virus has an important etiologic role in HBsAg negative chronic hepatitis and liver cirrhosis in Korea. The diagnostic value of Lucky HCD EIA test may be slightly better or equivalent to Ortho HCV ELISA test in the diagnosis of Hepatitis C virus infection.

냉동 제대혈 세포의 체외 증폭

김삼용,김철희,배광봉,김현수,박상준,김종숙,윤환중,조덕연 大韓血液學會 1997 大韓血液學會誌 Vol.32 No.3

Expression and functional roles of the chemokine receptor CXCR7 in acute myeloid leukemia cells

Kim, Ha-Yon,Lee, So-Yeon,Kim, Deog-Young,Moon, Ji-Young,Choi, Yoon-Seok,Song, Ik-Chan,Lee, Hyo-Jin,Yun, Hwan-Jung,Kim, Samyong,Jo, Deog-Yeon Korean Society of Hematology; Korean Society of Bl 2015 Blood Research Vol.50 No.4

<P><B>Background</B></P><P>The C-X-C chemokine receptor 7 (CXCR7) has been shown to be a decoy receptor for CXCR4 in certain cell types. We investigated the expression status and functional roles of CXCR7 in acute myeloid leukemia (AML) cells <I>in vitro.</I></P><P><B>Methods</B></P><P><I>CXCR7</I> mRNA was knocked down in AML cells by using small interfering RNA (siRNA) technology, and subsequent biological alterations in the cells were evaluated <I>in vitro.</I></P><P><B>Results</B></P><P>All AML cell lines examined in this study (U937, K562, KG1a, HL-60, and MO7e) and primary CD34<SUP>+</SUP> cells obtained from patients with AML expressed <I>CXCR7</I> mRNA at various levels. Western blotting showed that all AML cells produced CXCR7. Furthermore, all AML cells expressed CXCR7 in both the cytoplasm and on the cell surface at various levels. Stromal cell-derived factor-1 (SDF-1; C-X-C motif ligand 12 (CXCL12)) induced internalization of cell surface CXCR7. However, neither hypoxia nor the examined hematopoietic growth factors (interleukin-1β (IL-1β), IL-3, IL-6, granulocyte-colony-stimulating factor, granulocyte, macrophage-colony-stimulating factor, and stem cell factor) and proinflammatory cytokines (interferon-γ, transforming growth factor-β, and tumor necrosis factor-α) were found to alter cell surface CXCR7 expression. The transfection of AML cells with <I>CXCR4</I> siRNA, but not <I>CXCR7</I> siRNA, significantly impaired the CXCL12-induced transmigration of the cells. The transfection of AML cells with <I>CXCR7</I> siRNA did not affect the survival or proliferation of these cells. Knockdown of <I>CXCR7</I>, but not <I>CXCR4</I>, induced the upregulation of <I>CXCL12</I> mRNA expression and CXCL12 production in AML cells.</P><P><B>Conclusion</B></P><P>CXCR7 is involved in the regulation of autocrine CXCL12 in AML cells.</P>

골융해 골전이가 있는 악성종양 환자에서 Oral clodronate의 임상적 치료효과

김종숙,곽상혁,강정현,김철희,배광봉,김현수,박상준,최지영,윤환중,조덕연,김삼용 충남대학교 의과대학 지역사회의학연구소 1997 충남의대잡지 Vol.24 No.1

The skeleton is common metastatic site for cancer. Although bone metastases are not usually life-threatening, they are often the cause of severe morbidity and can produce clinical problems of both acute and a chronic nature. Characteristically. patients experience severe bone pain and pathologic fracture. Hypercalcemia and hypercalciura can occur when the metastatic lesions are predominantly osteolytic and are often worsened by the immobility that results from excessive skeletal pain, especially when weight-bearing bones are involved. The bisphosphonates are enzyme-resistant analogues of pyrophosphate, the naturally occuring inhibitor of bone mineralisation. They bind to hydroxyapatite crystals, inhibit osteoclast-mediated bone resorption. The clinical effect of oral clodronate was assessed in 20 patients with advanced cancer associated with osteolytic bone metastases in an open trial of 4 week duration. The dose was 800-1,600mg/day. The level of calcium on day 7 in hyercalcemic patients was significantly reduced by oral clodronate treatment(p<0.05). In normocalcemic patients the serum calcium level did not change significant statistically after coldronate treatment. The subjective improvement of pain was seen in 60% of patients. The side effect of clodronate was nausea and vomiting but tolerable. In conclusion, oral coldronate provided effective control hypercalcemia and pain associated with osteolytic bone metastases and was well tolerated.

후두암의 치료 성적

김성은,신현영,곽승근,박상은,박수진,윤환중,조덕연,김삼용,김병국 충남대학교 의과대학 의학연구소 2002 충남의대잡지 Vol.29 No.1

Laryngeal cancer-the most common malignant tumor within head and neck-is known for its better prognosis when we compare with the other malignancies. In this paper, We analyzed retrospectively results of operation, radiotherapy and chemotherapy of laryngeal cancer to find out the response rate, survival rate and prognostic factor. 75 consequent laryngeal cancer patients who have been treated at CNUH during the period of 1995 to 2000 were studied. The patients are consisted of 72 males and 3 females. The primary site were; glottis in 45 patients, supraglottis in 29 patients, and subglottis in 1 patient. 96% had squamous cell carcinoma and 98% of evaluable patients had history of smoking. Glottic cancer was detected earlier and showed much better prognosis than supraglottic cancer (p <0.001). 45 patients received radiotherapy while 17 patients underwent surgery and post -operative radiotherapy. Complete remission rate after radiotherapy was 85.7% in glottic cancer patient. Three year overall survival rate was 85.4 % in total. Significant prognostic factor for 3-year overall survival and 3-year disease free survival on univariate analysis were stage, T stage, and primary site. 3-year overall survival rate was higher in patients with negative lymph node involvement. Progression or recurrence usually occurred within 12 months in responsive group. Chemotherapy was the primary treatment modality in 9 patients and 6 patients recieved additive radiotherapy. Among 9 patients, 2 patients obtained complete remission and 1 patient achieved partial response after subsequent radiotherapy. Advanced cancer patients after surgery with radiotherapy achieved high survival rate, but lost larynx function. We need to develop better strategies to increase both voice preservation and survival rate in patients with advanced laryngeal cancer.

단기간의 저용량 Cytosine arabinoside 치료에 반응하였던 Down 증후군에 병발한 급성골수성백혈병 1례

김현수,이정호,이정찬,강정현,곽상혁,김철희,배광봉,김종숙,조덕연,김삼용 충남대학교 의과대학 지역사회의학연구소 1998 충남의대잡지 Vol.25 No.1

The incidence of hematologic disorders in patients with Down's syndrome is significantly increased, about 14∼30 - fold higher than in general population and includes neonatal transient abnormal myelopoieis and acute leukemias. The age of onset of leukemia in Down's syndrome is peaking first in the newborn period and then under 4 years of age. Down's syndrome with acute leukemia above the age of 20 is very rare and it's treatment oucome is unclear. The treatment of Down's syndrome with leukemia has been controversial because of toxicity and associated congenital cardiac and other abnormalities. But if treated adequately, children with Down's syndrome show a favorable response to anti-leukemia therapy. A 24-year-old man with Down's syndrome was first seen for the evaluation of anemia and thrombocytopenia. The peripheral blood morphology and bone marrow study revealed acute myelogenous leukemia, cytogenetic study of bone marrow showed trisomy 21. Beacuse of his sicioeconomic condition and medical abnormalities including deafness, visual loss, he was treated with low dose subcutaneous cytosine arabinoside(Ara-C) for 11 days. Complete remission was obtained after 37 days. The complete remission lasted for 5 months. He subsequently relapsed, and died 6 months later.

Dexamethasone and hypoxia upregulate CXCR4 expression in myeloma cells

Kim, Seong-Woo,Kim, Ha-Yon,Lee, Hyo-Jin,Yun, Hwan-Jung,Kim, Samyong,Jo, Deog-Yeon Informa UK Ltd 2009 Leukemia & lymphoma Vol.50 No.7

<P>We investigated the modulation of CXCR4 expression by cytokines, dexamethasone, and hypoxia in myeloma cells <I>in ?vitro</I>. Tumor necrosis factor-alpha ((TNF-α慣)), transforming growth factor-beta1 ((TGF-β棺1)), and vascular endothelial growth factor ((VEGF)) enhanced CXCR4 expression in RPMI8226 cells. In the myeloma cell lines examined and primary bone marrow ((BM)) CD138++ cells, dexamethasone enhanced CXCR4 expression both in the cytoplasm and on the cell surface, while downregulating SDF-1 expression and secretion in BM stromal cells. Incubation of cells under hypoxic conditions ((1%% O<SUB>2</SUB>)) also induced upregulation of CXCR4 in the cytoplasm and on the cell surface and enhanced chemotaxis in response to stromal cell-derived factor-1 ((SDF-1)). Cell surface CXCR4 expression was more prominent in annexin V-positive apoptotic cells. Given the roles of the SDF-1//CXCR4 axis in the development and progression of myeloma, CXCR4-downregulating agents may enhance the antitumor effects of dexamethasone.</P>

항암제 처리한 백혈병 세포주에서의 Apoptosis 발현

김삼용,윤소현,김현수,김종숙,윤환중,김진경,조덕연 충남대학교 의과대학 지역사회의학연구소 1998 충남의대잡지 Vol.25 No.1

The bcl-2 proto-oncogene encodes a 26 kD protein that promotes cell survival by blocking apoptosis. The bax protein is a member of the bcl-2 familly, now known to form heterodimers with the bcl-2 protein. The ratio of bax to bcl-2 is be critical in determining the fate of the cell in response to stimuli that can induce apoptosis. Extract of Pulsatilla Koreana (SB-31) showed promising antitumor activity in vitro with Topo I inhibitory action. In the present study, the relationship between apoptosis and the apoptosis related proteins, bcl-2 and bax were investigated in human leukemic cell lines HL-60, U-937 and CEM-CM3. All anticancer drugs(adriamycin, etoposide, camptothecin, SB-31) induced extensive apoptosis in HL-60, U-937 cells and CEM-CM3 cells. The expression of bcl-2 and bax protein were determined in cell lines by western blotting before and after incubation with anticancer drugs at different time points. 1) In HL-60 or U-937 cell lines, down regulation of bcl-2 and up-regulation of bax were found after incubation with ADR, VP-16 or camptothecin. 2) In HL-60 or U-937 cell lines, no significant change in bcl-2 or bax protein expression resulted after incubation with SB-31. 3) In CEM-CM3 cells, virtually no change was noted in bcl-2/bax expression after incubation with ADR, VP-16, camptothecin or SB-31. It is suggested that different leukemic cell lines use different pathways of apoptosis activation and a given cell may utilize different pathways of apoptosis activation in response to different cytotoxic agents.

Cisplatin 병용화학요법으로 인한 오심, 구토의 예방을 위한 Granisetron(Kytril^ⓡ)과 MDL(Meroclopramide, Dexamethasone, Lorazepam) 병용요법의 비교

김삼용,김철희,배광봉,김현수,박상준,김종숙,최지영,윤환중,조덕연 충남대학교 의과대학 지역사회의학연구소 1997 충남의대잡지 Vol.24 No.1

Granisetron is known as the most selective 5-HT3 receptor antagonist and is reported to be effective in the prevention of acute emesis induced by cisplatin based chemotherapy. From June 1885 to December 1995, 32 solid tumor patients who were scheduled to receive cisplatin based combination chemotherapy were randomized either to granisetron or MDL(Metoclopramide, Dexamethasone, Lorazepam) prophylaxis. We evaluated 32 patients; 17 patients received granisetron 3mg, while 15 patients received MDL. The male to female ration was 12:5(Granisetron group) versus 12:3(MDL group), and moan age was 44.6 yrs(Granisetron group) versus 46.5 yrs(MDL group). Of 17 granisetron treated patients, 76.5%(13/17) obtained complete or major response in prevention of acute emesis, while 73.4%(11/15) of patients receiving MDL on first 24 hours of chemotherapy(P>0.05). No severe side effects were recorded in both groups. In granisetron group, mild headache and constipation were noted. In MDL group, the most common side effect was sedation(4/15, 26.7%), but extrapyramidal reaction was not noted in our patients. These results show that granisetron is an effective antiemetic in the control of cisplatin induced nausea and vomiting, and can be administered safely with minimal side effects.

혈우병 환자에 동반된 자발성 후복막강 출혈

김광일,김동호,우상민,이석주,김홍성,조인성,윤환중,조덕연,김삼용 충남대학교 의과대학 지역사회의학연구소 1997 충남의대잡지 Vol.24 No.1

Spontaneous retroperitoneal hemorrhage due to hemophilia A with impaired coagulopathy is very rare. Spontaneous retroperitoneal hemorrhage has been recorded as having originated from many retroperitoneal organs and blood vessels, and it may be due to local and/or systemic factors. In the majority of the patients, kidney and adrenal gland were the major site of hemorrhage. The systemic causes of spontaneous retroperitoneal hemorrhage are anticoagulation therapy and chronic hemodialysis. During the course of these treatments, hemorrhagic complications may occur at many site, including the retroperitoneal space. Blood dyscrasias including leukemia, polycythemia, sickle cell trait and hemophilia have been reported associated with spontaneous retroperitoneal hemorrhage. We report a case of spontaneous retroperitoneal hemorrhage occurred in a gemophilia A patient with brief review of literature